Yale University has agreed to screen access – with Johnson & Johnson’s input – to detailed clinical trial data on the pharmaceutical giant’s products. Outside academic researchers interested in conducting safety, efficacy and other studies will have access to the “entire trove of clinical trial data assets and they have given us complete authority and jurisdiction over all decisions regarding data access,” according to Dr. Harlan Krumholz, the project’s head.
Of note:
The article tells a story of the conversation between Dr. Krumholz and Joanne Waldstreicher, J&J’s chief medical officer, that lead to this agreement:
“During a long walk on the Yale campus, both doctors said, Dr. Krumholz told her he was disappointed that more companies weren’t showing more leadership in making their data available for independent research.
“Dr. Krumholz said that by not making such data “more widely available, we were compromising the promise” patients made to contribute to the good of society by participating in the studies.
“Dr. Waldstreicher took the argument to the company, which led to the new agreement.”
